Standard Operating Procedure (SOP)

Research Safety Reporting Standard Operating Procedure

<table>
<thead>
<tr>
<th>Date</th>
<th>Version</th>
<th>Reason for change</th>
<th>Author/Responsible person</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original policy</td>
<td>September 2005</td>
<td></td>
<td>Research and Development Manager (Governance and Quality)</td>
</tr>
<tr>
<td>Review</td>
<td>September 2008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Review</td>
<td>August 2011</td>
<td>3.4 Minor change to errors in addresses</td>
<td></td>
</tr>
<tr>
<td>Update</td>
<td>February 2012</td>
<td>3.5 Change from annual reporting to Development Safety Update Reporting</td>
<td>Research Operations Manager</td>
</tr>
<tr>
<td>Review &amp; Update</td>
<td>February 2012</td>
<td>4.0 Change from annual reporting to Development Safety Update Reporting</td>
<td>Research Operations Manager</td>
</tr>
<tr>
<td>Approved</td>
<td>February 2012</td>
<td>4.0 Changes to out of date website links and clarification on responsibilities of research team.</td>
<td>Deputy Director of Research and Innovation</td>
</tr>
<tr>
<td>Review &amp; Update</td>
<td>March 2013</td>
<td>5.0 Clarification of process of reporting and updates to website links.</td>
<td>Acting Research Operations Manager.</td>
</tr>
<tr>
<td>Review &amp; Update</td>
<td>April 2014</td>
<td>6.0 Clarification of process of reporting, updates to website links and minor changes to reporting templates</td>
<td>Research Operations Manager</td>
</tr>
<tr>
<td>Review &amp; Update</td>
<td>February 2015</td>
<td>7.0 Clarification of process of reporting, updates to website links and minor changes to reporting templates</td>
<td>Research Operations Manager</td>
</tr>
<tr>
<td>Review date</td>
<td>Version number</td>
<td>Version Date</td>
<td>Effective Date</td>
</tr>
<tr>
<td>---------------------</td>
<td>----------------</td>
<td>--------------</td>
<td>----------------</td>
</tr>
<tr>
<td>September 2015</td>
<td>V8.0</td>
<td>12/10/2015</td>
<td></td>
</tr>
</tbody>
</table>

Acknowledgements:

1. Ms Tanya Symons; T Symons Associates Ltd. 154 Tivoli Crescent North, Brighton, East Sussex.
2. North Bristol NHS Trust
1 Background, guidance and legislation

1.1 In 2001 the Government published the Research Governance Framework for Health and Social Care. Enquiries into adverse incidents relating to research have criticised the lack of clarity in relation to responsibilities and accountabilities for research in health and social care. This is of particular importance, given the very wide range of individuals and organisations that can be involved in research. The Framework pays particular attention to clarifying responsibilities and accountabilities with the aim of forestalling research related adverse incidents. In accordance with the Research Governance Framework for Health and Social Care UH Bristol must have systems in place to record, investigate and report adverse incidents arising from any research undertaken within the Trust.

1.2 The Medicines for Human Use (Clinical Trials) Regulations 2004 came into force on the 1st May 2004. These regulations including any amendments apply to all clinical trials involving investigational medicinal products (CTIMPs) and specify the reporting requirements for research related adverse events. To breach these requirements constitutes a breach in criminal law. The requirements have been incorporated within this policy.

1.3 In the same way that adverse incidents, including clinical, non-clinical and near misses can involve patients, staff and visitors during routine care, adverse incidents can also occur during research related activities. It is important that research related adverse incidents are treated in the same way as non-research related adverse incidents.

1.4 All Trusts have a responsibility to report adverse incidents relating to research to the National Patient Safety Agency.
1.5 For CTIMPs, Updated guidance (Development Safety Update Report (DSUR) – ICH E2F) was published in September 2010 in the EU and was implemented in September 2011. DSUR should be provided at yearly intervals from the date of the original exemption, for trials ongoing on 1 May 2004, or the date of the first CTA approval for trials starting after 1 May 2004. For trials with marketed products the date is the first marketing authorisation granted in the EU. The purpose of the DSUR is to introduce a common standard for periodic reporting on drugs under development among the ICH regions, highlighting new safety issues and giving a current safety profile of an IMP.

2 Scope

2.1 Recording and reporting of Adverse Events, including Adverse Reactions, Serious Adverse Events, Serious Adverse Reactions and Suspected Unexpected Serious Adverse Reactions will be managed in line with the reporting policy of the sponsor of the research study. Where UH Bristol is the sponsor, where no sponsor policy exists, or where the minimum reporting requirements laid out within the UH Bristol Research Safety Reporting SOP are not met, this SOP must be followed as a minimum.

2.2 Recording and reporting of breaches concerning patient safety

3 Abbreviations and definitions

3.1 Abbreviations

<table>
<thead>
<tr>
<th>Abbreviations</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>AI</td>
<td>Adverse Incident</td>
</tr>
<tr>
<td>AR</td>
<td>Adverse Reaction</td>
</tr>
<tr>
<td>CI</td>
<td>Chief Investigator</td>
</tr>
<tr>
<td>CTIMP</td>
<td>Clinical trial of an Investigational Medicinal Product</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>HR</td>
<td>Health Research Authority</td>
</tr>
<tr>
<td>IMP</td>
<td>Investigational Medicinal Product</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>MHRA</td>
<td>Medicines and Healthcare products Regulatory Agency</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>REC</td>
<td>Research Ethics Committee</td>
</tr>
<tr>
<td>R&amp;I</td>
<td>Research and Innovation</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>SAR</td>
<td>Serious Adverse Reaction</td>
</tr>
<tr>
<td>SSAR</td>
<td>Suspected Serious Adverse Reaction</td>
</tr>
<tr>
<td>SUSAR</td>
<td>Suspected Unexpected Serious Adverse Reaction</td>
</tr>
<tr>
<td>UHBristol</td>
<td>University Hospitals Bristol NHS Foundation Trust</td>
</tr>
<tr>
<td>UoB</td>
<td>University of Bristol</td>
</tr>
</tbody>
</table>

3.2 Definitions
3.2.1 **An adverse event** is any untoward medical occurrence in a subject to whom a medicinal product/medical device/intervention has been administered, including occurrences which are not necessarily caused by or related to that product.

*Comment: An adverse event can therefore be any unfavourable and unintended sign (including abnormal lab results), symptom or disease temporarily associated with the use of the medicinal product/medical device/intervention, whether or not considered to be related to the medicinal product/medical device/intervention.*

3.2.2 **An adverse reaction** is any untoward and unintended response in a subject to an investigational medicinal product/medical device/intervention which is related to any dose administered to that subject.

*Comment: Any adverse event judged by either the reporting investigator or the sponsor as having reasonable causal relationship to a medicinal product/medical device/intervention qualifies as an AR; there is evidence or argument to suggest a causal relationship. All adverse reactions are adverse events.*

3.2.3 **An unexpected adverse reaction** is an adverse reaction, the nature and severity of which is not consistent with the information set out in:

(a) in the summary of product characteristics (for a product with a marketing authorisation),

(b) in the investigator's brochure (for any other investigational medicinal product).

*Comment:
(i) This applies to the medicinal product/medical device/intervention in question
(ii) When the outcome of the adverse reaction is not consistent with the applicable product information this adverse reaction should be considered as unexpected. All unexpected adverse reactions are adverse events.*

3.2.4 **An adverse event, adverse reaction or unexpected adverse reaction** is defined as serious if it:

(a) results in death,

(b) is life-threatening,

(c) requires hospitalisation or prolongation of existing hospitalisation,

(d) results in persistent or significant disability or incapacity, or

(e) consists of a congenital anomaly or birth defect.

*Comment: Life threatening in the definition of an SAE or SAR refers to an event in which the subject was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe. Medical judgement should be exercised in deciding whether an SAE/SAR is serious in other situations. Important SAE/SARs that are not immediately life-threatening or do not result in death or hospitalisation but may jeopardise the subject or may require intervention to prevent one or the other outcomes listed in the definition above, should also be considered serious.*

3.2.5 **A suspected serious adverse reaction** (SSAR), is any serious adverse reaction that is suspected (possibly or probably or definitely) to be related to the
investigational medicinal product/medical device/intervention.

3.2.6 **A suspected unexpected serious adverse reaction (SUSAR)** is an SSAR which is also “unexpected”, meaning that its nature and severity are not consistent with the information about the medicinal product in question set out:

(a) in the case of a product with a marketing authorisation, in the summary of product characteristics for that product
(b) in the case of any other investigational medicinal product, in the investigator’s brochure relating to the trial in question.

3.2.7 Not all adverse events are adverse reactions but all adverse reactions are adverse events.

3.2.8 **An Investigational Medicinal Product** is a pharmaceutical form of an active substance or placebo being tested or used as a reference in a clinical trial including a medicinal product which has a marketing authorisation but is, for the purposes of the trial being used or assembled (formulated or packaged) in a way different from the approved form or being used for an unapproved indication or when used to gain further information about an approved use.

3.2.9 **A non-IMP SUSAR** is an SAE that occurs in a non-IMP trial and is:

- “Related” – that is, possibly, probably or definitely resulted from administration of any of the research procedures, and
- “Unexpected” – that is, the type of event is not listed in the protocol as an expected occurrence.

3.2.10 The sponsor and investigator may take appropriate **Urgent Safety Measures (USMs)** to protect a research participant from an immediate hazard to their health and safety. This measure can be taken before seeking approval from the competent authorities (MHRA in the UK) and ethics committees of all member states concerned ([http://www.ct-toolkit.ac.uk/routemap/urgent-safety-measures](http://www.ct-toolkit.ac.uk/routemap/urgent-safety-measures)). A protocol amendment must be submitted; details are located on the MHRA website.

3.2.11 The sponsor of a clinical trial is obliged to notify the licensing authority in writing of any **serious breach** of –

(a) the conditions and principles of GCP in connection with that trial; or
(b) the protocol relating to that trial, as amended from time to time in accordance with regulations 22 to 25, within 7 days of becoming aware of that breach.

For the purposes of this regulation, a “serious breach” is a breach which is likely to effect to a significant degree – (a) the safety or physical or mental integrity of the subjects of the trial; or (b) the scientific value of the trial. Further details can be found on the MHRA website. This SOP describes the mechanism of assessing or reporting a serious breach of GCP or the protocol relating to patient safety.
4 Investigator Responsibilities

4.1 All Adverse Events

4.1.1 The Investigator must ensure that the dignity, rights, safety and well-being of subjects are given priority at all times and must take appropriate action to ensure the safety of all staff and patients in the study. The Investigator will consider what actions, if any, are required and in what timeframe.

4.1.2 Action necessitating amendments to the research protocol will require ethical, R&I and MHRA (IMP studies and non-CE marked devices only) approval through the usual routes. Amendments requiring immediate changes to the protocol (e.g. urgent safety measures) will be implemented and then submitted for ethical, R&I and MHRA (IMP studies and non-CE marked devices only) approval. The initial notification should be by telephone. Notice in writing to REC, R&I and MHRA should be sent within three days. The notice should set out the reasons for the urgent safety measures and plan for further action.

4.1.3 The Investigator is responsible for ensuring that all adverse incidents, whether or not related to research, are reported in accordance with the University Hospital Bristol's Serious Incident Policy and associated policies.

4.1.4 In the event of an adverse event/reaction, the investigator (or delegated member of research team) must review all documentation (e.g. hospital notes, laboratory and diagnostic reports) relevant to the event. The event and relevant comments must then be recorded in the subject’s medical notes (or source data where this is not the medical notes).

4.1.5 Except where the protocol states otherwise, all adverse event/reactions should be recorded in detail on a case record form or equivalent to allow analysis at a later stage. A template for recording adverse events is provided as an example in appendix 1.

4.1.6 For all adverse event/reactions the investigator will make an assessment of intensity, causality, expectedness and seriousness. In order to make this assessment the Investigator should refer to the latest SmPC or IB for the study IMP, and approved study Protocol. Intensity will not need to be recorded for expected adverse events unless the intensity is such that the event becomes unexpected as a result.

4.1.7 Adverse events and/or laboratory abnormalities identified in the protocol as critical to the evaluations of the safety of the study shall be reported to the sponsor in accordance with the reporting requirements documented in the protocol.

4.1.8 The Chief Investigator will keep the Sponsor and the main REC informed of any significant findings and recommendations by an independent Data Monitoring Committee or equivalent body where one has been established for the trial.

4.1.9 At the conclusion of the study all adverse event/reactions recorded during a study must be subject to statistical analysis as determined by the protocol and that
analysis and subsequent conclusions included in the final study report.

4.2 Serious Adverse Events

4.2.1 Within 24 hours of a member of the research team becoming aware of a serious adverse event the sponsor must be notified. The investigator (or delegated person) will make an initial report, orally or in writing. Oral reports will be followed up in writing within 24 hours of the initial report. Written reports will be made by completing an SAE/SUSAR reporting form provided by the sponsor of the research study. Where UH Bristol is the sponsor or where no form has been provided, the investigator will use the UH Bristol Research Related SAE/SUSAR Initial Report form (appendix 3). The initial report will include as much information as is available at the time.

4.2.2 In addition to 4.2.1 the following bodies must also be notified in a timely fashion. It is strongly recommended that this be at the same time as notifying the sponsor:

- The Chief Investigator
- Any other persons or bodies specified in the protocol (e.g. Data Safety Monitoring Board)

The only exception to sections 4.2.1 and 4.2.2 is where the protocol or Investigator’s Brochure identifies the event as not requiring immediate reporting.

4.2.3 After the initial report the investigator is required actively to follow up the subject. The investigator (or delegated person) will provide information missing from the initial report within five working days of the initial report to the bodies specified in section 4.2.1 and 4.2.2.

4.2.4 Investigators (or delegated persons) will provide follow-up information, each time new information is available, using the UH Bristol Research Related SAE/SUSAR Follow-up Report form (appendix 4) or form provided by the sponsor, until the SAE has resolved or a decision for no further follow up has been taken.

4.2.5 For all studies the Chief Investigator will inform all Principal Investigators of relevant information about SAEs that could adversely affect the safety of subjects.

4.2.6 The Chief Investigator will provide the main REC with copies of all reports and recommendations of any independent Data Safety Monitoring Board established for a trial.

4.2.7 For IMP studies, on request of the MHRA the Chief Investigator will submit detailed records of all adverse events that have been reported.

4.3 (Serious) Breaches

4.3.1 The Investigator and the research team have a responsibility to ensure that the research is conducted in accordance with the Protocol and Good Clinical Practice. Where there is a breach this must be assessed by the Investigator and reported to the Sponsor within 24 hours of becoming aware of the event (unless it is the
Sponsor that has identified the breach. This can be reported orally or in writing. Where UH Bristol is sponsor an assessment will be made by a member of the senior management team of whether the breach is serious, referring to the MHRA definitions, and whether onward reporting to regulatory authorities is required. After initial notification to the Sponsor a Corrective and Preventative Action form (Appendix 7) should be completed by the study team and signed by the Principal Investigator, and by a senior manager within R&I as Sponsor representative.

4.3.2 For serious breaches the MHRA and Ethics committee must be notified within 7 days of the breach being identified. Where UH Bristol are Sponsor the R&I department will liaise with the research team in order to make the required notification.

4.3.3 Where the breach has a potential impact on patient safety an assessment will be made by Sponsor and Principal Investigator of immediate actions required for example; halting the trial, withdrawing a participant, closing study sites. Where there is an urgent safety concern the Investigator will follow the required action, described below. Where there is no urgent safety concern the proposed action may be discussed with the MHRA prior to implementation.

4.3.4 The Research Management Facilitator allocated to the research must document all correspondence relating to the breach, complete the breaches log located on the R&I shared J Drive (safety section) and discuss with the R&I monitor whether any follow up monitoring actions are required.

4.3.5 Any non–serious breaches will be filed in the Investigator Site File and Trial Master File.

4.4 Urgent Safety Measures

4.4.1 The sponsor and investigator may take appropriate Urgent Safety Measures (USMs) to protect a research participant from an immediate hazard to their health and safety. This measure can be taken before seeking approval from the competent authorities (MHRA in the UK) and ethics committees of all member states concerned (http://www.ct-toolkit.ac.uk/routemap/urgent-safety-measures). The first action is to protect patient safety/health. Following that, where UHBristol is sponsor, the CI/PI on behalf of the sponsor should discuss the urgent safety measure by telephone as soon as it has been put in place with an MHRA safety scientist in the first instance. A protocol amendment must be submitted within the following three days to the MHRA, and ethics committee; details are located on the MHRA website. All communication between the MHRA, the CI/PI and the R&I office should be documented and placed in the ISF and TMF.

4.5 Data Safety Monitoring Boards

4.5.1 During trial set up it will be assessed by Sponsor and Chief Investigator whether a Data Safety Monitoring Board (DSMB) is required to provide essential oversight of the trial. The role and responsibility of the DSMB will be described in the Protocol and documented charter prior to study start.

Where a DSMB is put in place for a UH Bristol sponsored trial the expectation of the board and its functions will include but not be limited to the following;
- The members should be independent of Sponsor and CI
- The process for frequency of meeting and methods of communication should be documented in a charter prior to study start
- How reports from the board will be generated and process of how actions must be addressed in an efficient manner documented
- A member of the board or research team is delegated responsibility for maintaining the DSMB paperwork and acting as a liaison point between the DSMB, Sponsor and CI
- For blinded trials review unblinded data in order to maintain oversight of safety
- Provide recommendations to Sponsor or Trial Steering Committee (if in place) on trial design, protocol amendments, urgent safety measures etc.

Further information on DSMB can be found in the EMA ‘Guidance on data monitoring committees’ (EMEA/CHMP/EWP/5872/03). Where UH Bristol are Sponsor the requirements of a DSMB will be discussed during the Study Set Up and Management Plan (SUUMPP) and the expectation and processes documented in an agreed charter.

4.6 Development Safety Update reports

4.6.1 For CTIMPs, on the first anniversary of (a) the date of the first Clinical Trials Authorisation (CTA) approval (trials starting after 1 May 2004) (b) the date of the original exemption (trials commenced under an exemption) or (c) the date of the first marketing authorisation granted in the EU (marketed products) and thereafter annually until the regulator has been informed of the closure of the trial, a DSUR must be compiled and submitted. Preparation and submission of the DSUR will be the responsibility of the Chief Investigator, supported and co-ordinated by the sponsor if required. Submission should be made electronically (on a disk) to:

- Medicines and Healthcare products Regulatory Agency (MHRA) Information Processing Unit, Area 6, MHRA, 151 Buckingham Palace Road, Victoria, London. SW1W 9SZ

And either electronically on disk or via email to:

- Research Ethics Committee that granted approval.

Appendix 8 and 9 provide guidance and templates for DSU reports.

4.6.2 Each submission of an annual safety report to the REC must be accompanied by the Safety Report form for CTIMPs. This form is available to download from the HRA website.

5 Annual progress reports

5.1 Annual progress reports should be submitted thereafter until the end of the study

5.2 For all studies (IMP and non-IMP studies), 1 year following the granting of a favourable ethical opinion and thereafter annually, the Chief Investigator will submit progress reports to the Research Ethics Committee. These reports will include information on the safety of participants and are required in addition to the annual
safety report. The form for providing these reports is available on the HRA website.

5.2.1 For blinded studies where UH Bristol is sponsor, in compiling these reports, at the request of the Chief Investigator the Research and Innovation Department will provide any additional information required relating to the Sponsor’s assessment of SAEs. The Research and Innovation Department will take all reasonable efforts to ensure that no information that could unblind and therefore compromise the study is provided directly to the Chief Investigator, unless the Chief Investigator is already unblinded.

5.3 End of study reports

5.3.1 For non-IMP trials, at the end of the study the Chief Investigator will submit an end of study report to:
- Sponsor (where UH Bristol is the sponsor this will be the Research and Innovation Department).
- Research ethics committee that granted approval.
This report will be submitted on the declaration of end of study form which is available on the HRA website

5.3.2 For IMP trials, at the end of the study the Chief Investigator will submit an end of study report to:
- Sponsor (where UH Bristol is the sponsor this will be the Research and Innovation Department).
- Medicines and Healthcare products Regulatory Agency (MHRA) using the ‘Declaration of the end of a Clinical Trial’ form which is available on the MHRA website
- Research ethics committee that granted approval using the ‘EudraCT declaration of end of trial form’ which is available on the HRA website

5.3.3 For both IMP and non-IMP trials, within one year of the conclusion of the research a summary of the final report must be submitted to the Research Ethics Committee. There is no standard form for this.

5.3.4 For blinded studies where UH Bristol is sponsor, in compiling these reports, at the request of the Chief Investigator the Research and Innovation Department will provide any additional information required relating to the Sponsor’s assessment of SAEs. The Research and Innovation Department will take all reasonable efforts to ensure that no information that could unblind and therefore compromise the study is provided directly to the Chief Investigator, unless the Chief Investigator is already unblinded.

6 Department of Research and Innovation Responsibilities

6.1 Where UH Bristol is the sponsor of a blinded research study in which the SAE/SUSAR has occurred and where the Investigator and Sponsor have assessed that an unblinded assessment is required, the Research and Innovation Department will follow the unblinding process described within the approved study Protocol to make an unblinded assessment of intensity, causality, expectedness and seriousness using the criteria described in section 6. In making this assessment the Research and Innovation Department will consult the independent
Data Safety Monitoring Board (DSMB) for the study or, where a DSMB does not exist, a suitably medically qualified person. This unblinded assessor may be an investigator on the same study if unblinding him/her will not affect the conduct of the study in which the SAE has occurred; this will not be the person who made the initial assessment. NB A second assessment by the sponsor is not required where the investigator making the initial assessment is unblinded or where it is deemed unnecessary to make an unblinded assessment e.g, the event was expected.

6.2 The Research and Innovation Department will consider whether any actions, in addition to those already taken by the investigator, are required and will discuss these with the investigator.

6.3 In the event of a SUSAR occurring in a UH Bristol or University of Bristol sponsored CTIMP, a member of the Research & Innovation senior management team or delegated individual within the operations team will make an entry in the European database. The procedure is to log into the MHRA eSUSAR system: https://esusar.mhra.gov.uk/ using the login details which are located in the R&I shared J Drive within the monitoring folders (to which only R&I staff have access). The instructions given within the database will be followed. The R&I department will ensure that any SUSARs are reported within required timeframes regardless of who carries out the reporting.

6.4 The Research and Innovation Department reserves the right to suspend or withdraw sponsorship and NHS permission (or equivalent) for a study. This may happen, but is not limited to, where public health and safety is considered to be at risk, where the safety and well-being of research subjects or staff are considered to be at risk.

6.5 The Research and Innovation Department will maintain a record of all SAEs reported to the Department.

6.6 Non-IMP SUSARs

6.6.1 Where UH Bristol is the sponsor of a blinded non-IMP study, the Research and Innovation Department will delegate responsibility to the research team to report all SAEs that are assessed as non-IMP SUSARs. This assessment will be made by either the investigator or the un-blinded assessor. The report will be sent to the research ethics committee that granted approval within 15 days using the applicable form available on the HRA website.

7 SUSARs

7.1.1 This section applies only where UH Bristol is the sponsor of the research study using an IMP in which the SAE has occurred and where the investigator and/or sponsor has assessed the SAE to be a SUSAR.

7.1.2 The Research and Innovation Department will delegate responsibility to the research team to report all SUSARs that are fatal or life-threatening to:

- The Medicines and Healthcare products Regulatory Agency (MHRA)
- the competent authorities (equivalent of MHRA) of any EEA State, other than the United Kingdom, in which the trial is being conducted.
• The research ethics committee that granted approval\(^1\) within seven days of becoming aware of the event.

7.1.3 The Research and Innovation Department will delegate responsibility to the research team to report any additional relevant information to the bodies described in section 5.6.2 within eight days of the report described in section 5.6.2 being made.

7.1.4 The Research and Innovation Department will delegate responsibility to the research team to report all SUSARs that are not assessed as life threatening or fatal to:
- The Medicines and Healthcare products Regulatory Agency (MHRA)
- The competent authorities (equivalent of MHRA) of any EEA State, other than the United Kingdom, in which the trial is being conducted
- The research ethics committee that granted approval\(^1\) within 15 days of becoming aware of the event.

7.1.5 Initial notifications of SUSARs may be made by fax, e-mail or telephone. Follow-up reports and all other safety reports should be sent to the REC office by post or email.

7.1.6 Each submission of a SUSAR report to the REC must be accompanied by the Safety Report form for CTIMPs available on the HRA website.

A single form may be used for the submission of several safety reports relating to the same trial. Reports should not normally cover more than one trial. However, the REC may permit this where two trials are very closely connected, for example a main study and an extension study with the same treatment regime.

7.2 Development Safety Update, annual progress and end of study reports

7.2.1 Where UH Bristol is sponsor, at the request of the Chief Investigator the Research and Innovation Department will assist the Chief Investigator by co-ordinating the compilation of the Development Safety Update, annual progress and end of study reports. In meeting such requests the Research and Innovation Department will take all reasonable efforts to ensure that no information that could unblind and therefore compromise the study is provided directly to the Chief Investigator, unless the Chief Investigator is already unblinded.

8 Assessment of Adverse Events

8.1 Intensity

The assessment of intensity will be based on the investigator’s clinical judgement using the following definitions:
- **Mild**: An event that is easily tolerated by the patient, causing minimal discomfort and not interfering with everyday activities.
- **Moderate**: An event that is sufficiently discomforting to interfere with normal everyday activities.

\(^1\) In the case of the main REC, UH Bristol is only required to report in an expedited fashion SUSARs occurring in the UK.
• **Severe:** An event that prevents normal everyday activities.

  *Comment: The term *severity* is often used to describe the intensity (severity) of a specific event. This is not the same as ‘seriousness’, which is based on patient/event outcome or action criteria.*

### 8.2 Causality

The relationship between the drug/device/procedure and the occurrence of each adverse event will be assessed and categorised as below. The investigator will use clinical judgement to determine the relationship. Alternative causes, such as natural history of the underlying diseases, concomitant therapy, other risk factors etc. will be considered. The investigator will also consult the Investigator Brochure or other product information.

- **Not related:** Temporal relationship of the onset of the event, relative to administration of the product, is not reasonable or another cause can by itself explain the occurrence of the event.
- **Unlikely:** Temporal relationship of the onset of the event, relative to administration of the product, is likely to have another cause which can by itself explain the occurrence of the event.
- **Possibly related:** Temporal relationship of the onset of the event, relative to administration of the product, is reasonable but the event could have been due to another, equally likely cause.
- **Probably related:** Temporal relationship of the onset of the event, relative to administration of the product, is reasonable and the event is more likely explained by the product than any other cause.
- **Definitely related:** Temporal relationship of the onset of the event, relative to administration of the product, is reasonable and there is no other cause to explain the event, or a re-challenge (if feasible) is positive.

*Where an event is assessed as possibly related, probably related, or definitely related the event is an adverse reaction.*

### 8.3 Expectedness

Adverse reactions must be considered as unexpected if they add significant information on the specificity or severity of an expected adverse reaction. The expectedness of an adverse reaction shall be determined according to the reference documents as defined in the study protocol (e.g. Investigator Brochure or marketing information).

- **Expected:** Reaction previously identified and described in protocol and/or reference documents e.g. Investigator Brochure, Summary of Product Characteristics (SmPC).
- **Unexpected:** Reaction not previously described in the protocol or reference documents.

*NB The protocol must identify the reference documentation used.*

### 8.4 Seriousness

An event is considered serious if it meets one or more of the following criteria:

- Results in death
- Is life-threatening
- Requires hospitalisation or prolongation of existing hospitalisation
- Results in persistent or significant disability or incapacity
- Consists of a congenital anomaly or birth defect

9 References


2. The Medicines for Human Use (Clinical Trials) Regulations 2004 Statutory Instrument 2004 No. 1031
   http://www.legislation.hmso.gov.uk/si/si2004/20041031.htm#33

3. EMEA Detailed guidance on the collection, verification and presentation of adverse reaction reports arising from clinical trials on medicinal products for human use. April 2006

4. DSUR guidance: ICH E2F

RELATED DOCUMENTS
002/UHBristolR&I Sponsorship SOP
005/UH Bristol R&I Gaining & Maintaining Authorisation SOP

QUERIES
Research Operations Manager or Research Management Facilitators - Research & Innovation Department via 0117 342 0233
Appendix 1 - Adverse Events template

UH Bristol Investigator’s Template for recording Adverse Events

<table>
<thead>
<tr>
<th>AE No:</th>
<th>Patient ID</th>
<th>Description of Event</th>
<th>Start date</th>
<th>Duration/End date</th>
<th>Outcome</th>
<th><strong>Sequelae</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Resolved</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ongoing with sequelae**</td>
</tr>
</tbody>
</table>

Assessment

Intensity:
- □ mild
- □ moderate
- □ severe

Expectedness:
- □ expected
- □ unexpected i.e. not described in protocol, product information or Investigator Brochure.

Causality: Relationship to study drug/device/intervention
- □ not related
- □ unlikely to be related
- □ possibly related
- □ probably related
- □ definitely related

Seriousness
- □ Not serious
- □ Results in death*
- □ Life threatening*
- □ Results in hospitalisation or prolongation of existing hospitalisation*
- □ Results in disability or incapacity*
- □ Congenital anomaly or birth defect*
- □ Other (please specify)*

* Event is considered serious – report to the sponsor within 24 hours using the form provided. Where none is provided use the UH Bristol Research Related SAE/SUSAR Initial Report Form
Appendix 2 - Instructions for completion of SAE forms  

Instructions Page 1 of 2

An event/reaction is serious if it:
- results in death,
- is life threatening,
- results in persistent or significant disability/incapacity,
- requires hospitalisation,
- prolongs a current hospitalisation
- results in a congenital anomaly or birth defect.

This form must be used where UH Bristol is the sponsor of the research study in which the SAE has occurred or where no other form has been provided by the sponsor.

Instructions for completion of Initial and Follow up Report Forms (Appendices 3 & 4):

1. As soon as possible, and at the latest within 24 hours of becoming aware of event,
   - Complete the Initial Report Form and send to sponsor.
   - Where UH Bristol is sponsor;
     - email: research@uhbristol.nhs.uk OR
     - fax: 0117 342 0239
   - Where University Of Bristol is sponsor the form must be submitted to both UH Bristol (using details above) and the University of Bristol;
     - email: research.governance@bristol.ac.uk OR
     - fax: 0117 929 8383

   Please ensure that all sections have been completed.

2. As soon as possible, and at the latest within five days of becoming aware of the event,
   - Complete the Follow up Report Form and send to sponsor.
   - Where UH Bristol is sponsor;
     - email: research@uhbristol.nhs.uk OR
     - fax: 0117 342 0239
   Where University Of Bristol is sponsor the form must be submitted to both UH Bristol (using details above) and the University of Bristol;
     - email: research.governance@bristol.ac.uk OR
     - fax: 0117 929 8383

   Please ensure that all sections of the forms have been fully completed

NB: Points 1 and 2 may be done together, if within 24 hours of becoming aware of the event.
3. Complete and return (as above) further Follow-up Report Form(s) for data collected later than five days post SAE until the SAE has resolved or a decision for no further follow up has been taken.

4. Initial and Follow up Report Forms must be signed off by the appropriate personnel and sent to the sponsor. Where UH Bristol is sponsor forms may be provided in paper, fax or electronic format. Paper copies to be sent to Research and Innovation, Level 3, UH Bristol Education Centre, Upper Maudlin Street, Bristol, BS2 8AE (not required if signatures on faxed copy). Faxed forms to be sent to 0117 342 0239 as detailed above. Electronic forms can be submitted via email to research@uhbristol.nhs.uk. Where the forms are submitted via email the scanned copy must include the signature of the CI/PI or alternatively be sent from the CI/PI email account as confirmation of signature.

5. For multi-centre studies where CI is not investigator making this report, send a copy of each form to the Chief Investigator.

6. Send a copy of each form to other bodies as required. e.g. Data Safety Monitoring Board.

7. Keep original forms in Investigator Site File (ISF).

8. Identifiable information must not be sent to sponsor unless; patient consent allows sponsor access, it is essential and it is sent via a secure method.
Appendix 3 - SAE initial report form

<table>
<thead>
<tr>
<th>UH Bristol/UoB reference number</th>
<th>R&amp;I case reference number (R&amp;I use only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject ID/Initials</td>
<td>Study site:</td>
</tr>
<tr>
<td></td>
<td>Onset date of SAE</td>
</tr>
</tbody>
</table>

SAE/SUSAR INITIAL REPORT FORM (Page 1 of 5)

1. Study Title (use short title where available):

2. Details of subject affected by SAE/SUSAR

Subject study ID:
Initials

3. Details of SAE/SUSAR (further space available in section 12)

Event name/ summary
(to be used as quick reference of event):

<table>
<thead>
<tr>
<th>Onset Date (when event became serious)</th>
<th>Date investigator/research team became aware of event</th>
<th>End date and time (if applicable)</th>
<th>OR Duration</th>
</tr>
</thead>
</table>

Full description of event/reaction, including body site, reported signs and symptoms and diagnosis where possible:

Event is defined as serious because it (tick as many as apply):
- [ ] resulted in death
- [ ] is/was life-threatening
- [ ] resulted in persistent or significant disability/incapacity
- [ ] required hospitalisation
- [ ] prolonged an ongoing hospitalisation
- [ ] resulted in a congenital anomaly or birth defect
- [ ] other – please specify*

Please give further details in section 6 ‘Outcome’

Maximum intensity if not life threatening or results in death (up until time of initial report)
- [ ] Mild
- [ ] Moderate
- [ ] Severe

*Specify:
To be completed by person filling in the SAE form

<table>
<thead>
<tr>
<th>UH Bristol/UoB reference number</th>
<th>R&amp;I case reference number (R&amp;I use only)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Subject ID/Initials</th>
<th>Study site:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Onset date of SAE</td>
</tr>
</tbody>
</table>

**SAE/SUSAR INITIAL REPORT FORM**

(Page 2 of 5)

Sheet number: ____ of ____

### 4. Details of IMP/device/intervention(s) if applicable

(further space available in section 12)

<table>
<thead>
<tr>
<th>Brand name:</th>
<th>Indication</th>
<th>Batch no.</th>
<th>Route (e.g. oral)</th>
<th>Form (e.g. tablet)</th>
<th>Total dose/24h (specify units)</th>
<th>Regimen (e.g. BD)</th>
<th>Start date &amp; time</th>
<th>Stop date &amp; time</th>
<th>Suspected cause of SAE/SUSAR? (Y/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For blinded studies, was the randomisation code broken?  
*Yes  □  *No  □  N/A □

*If yes, give details:

Continue on new sheet if necessary; please identify how many sheets have been used.
To be completed by person filling in the SAE form

<table>
<thead>
<tr>
<th>UH Bristol/UoB reference number</th>
<th>R&amp;I case reference number (R&amp;I use only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject ID/Initials</td>
<td>Study site:</td>
</tr>
<tr>
<td>Onset date of SAE</td>
<td></td>
</tr>
</tbody>
</table>

**SAE/SUSAR INITIAL REPORT FORM**  (page 3 of 5)

5. **Outcome** (further space available in section 12)

| □ Resolved* | □ Ongoing* | □ Died* (give cause and PM details if available) |

*Give details:

Was the patient withdrawn from the study?   Yes [ ]  No [ ]

6. **Location of (onset of) SAE** (further space available in section 12)

Setting (e.g. hospital*, home, GP, nursing home):

*If SAE occurred on UH Bristol precinct give exact location:

7. **Action taken and further information** (further space available in section 12)

Please describe action taken (including details of IMP where applicable e.g. drug withdrawn etc...):

Other information relevant to assessment of case e.g. medical history, family history, test results.

8. **Causality and Expectedness** (to be completed by physician)

<table>
<thead>
<tr>
<th>Is the SAE related to the drug/device/intervention?</th>
<th>In addition to this form, and within 5 days:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ Not related</td>
<td>1For unexpected SAEs, if event ongoing, please complete and return all sections of the follow up</td>
</tr>
<tr>
<td>□ Unlikely to be related</td>
<td></td>
</tr>
</tbody>
</table>

In addition to this form, and within 5 days:

1For unexpected SAEs, if event ongoing, please complete and return all sections of the follow up
Please refer to http://www.uhbristol.nhs.uk/research-innovation to ensure latest version of document is in use. Printed copies are Uncontrolled.
<table>
<thead>
<tr>
<th>To be completed by person filling in the SAE form</th>
</tr>
</thead>
<tbody>
<tr>
<td>UH Bristol/UoB reference number</td>
</tr>
<tr>
<td>Subject ID/Initials</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

12. Details of person completing this report (if different to CI/PI/delegated other above)

<table>
<thead>
<tr>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Job title/role in study:</td>
</tr>
<tr>
<td>Contact details</td>
</tr>
<tr>
<td>Signature</td>
</tr>
</tbody>
</table>

I confirm that the contents of this form (pages 1, 2, 3, 4 + 5) are accurate and complete
To be completed by person filling in the SAE form

<table>
<thead>
<tr>
<th>UH Bristol/UoB reference number</th>
<th>R&amp;I case reference number (R&amp;I use only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject ID/Initials</td>
<td>Study site:</td>
</tr>
<tr>
<td>Onset date of SAE</td>
<td></td>
</tr>
</tbody>
</table>

1. Further details of SAE/SUSAR

**Event name/ summary (to be used as quick reference of event):**

Further details of event/reaction, including body site, reported signs and symptoms and diagnosis where possible:

<table>
<thead>
<tr>
<th>Maximum intensity (up until time of follow up report)</th>
<th>Mild □</th>
<th>Moderate □</th>
<th>Severe □</th>
</tr>
</thead>
</table>

2. Outcome

| ☐ Recovered | ☐ Recovering | ☐ Not recovered | ☐ Recovering with sequelae | ☐ Fatal (give cause and PM details if available) | ☐ Unknown |

Give details:

<table>
<thead>
<tr>
<th>End date and time (where applicable)</th>
<th>OR Duration</th>
</tr>
</thead>
</table>

Was the patient withdrawn from the study? Yes □ No □

3. Additional action taken and further information since initial report

Please describe further action taken:
Further information or missing data relevant to assessment of case e.g. medical history, family history, test results.

Signature of person making report: ___________________________ Date: ___ / ___ / ___

Name (please print): ___________________________
Job title: ___________________________

Signature of Chief /Principal Investigator or delegated physician:
Name (print please):

I confirm that the contents of this form (pages 1, 2 ± 3/4) are accurate and complete.
### 4. CONCOMITANT MEDICATION – details of administration of other medication concurrent with the IMP(s)/device/intervention.

<table>
<thead>
<tr>
<th>Brand name:</th>
<th>Indication</th>
<th>Route (e.g. oral)</th>
<th>Form (e.g. tablet)</th>
<th>Total dose/24h (specify units)</th>
<th>Regimen (e.g. BD)</th>
<th>Start date &amp; time</th>
<th>Stop date &amp; time</th>
<th>Or duration of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continue on new sheet if necessary; please identify how many sheets have been used.
## SAE/SUSAR FOLLOW UP REPORT FORM

### To be completed by person filling in the SAE form

<table>
<thead>
<tr>
<th>UH Bristol/UoB reference number</th>
<th>R&amp;I case reference number (R&amp;I use only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject ID/Initials</td>
<td>Study site:</td>
</tr>
<tr>
<td></td>
<td>Onset date of SAE</td>
</tr>
</tbody>
</table>

### 5. STUDY IMP – details of administration. **NB complete for IMP studies only**

<table>
<thead>
<tr>
<th>Brand name:</th>
<th>Indication</th>
<th>Batch no.</th>
<th>Route (e.g. oral)</th>
<th>Form (e.g. tablet)</th>
<th>Total dose/24h (specify units)</th>
<th>Regimen (e.g. BD)</th>
<th>Start date &amp; time</th>
<th>Stop date &amp; time</th>
<th>Or duration of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For blinded studies, was the randomisation code broken?  
☐ ☐ ☑ ☐ *Yes ☐ ☐ No ☐ N/A

*If yes, give details:

**Continue on new sheet if necessary; please identify how many sheets have been used.**
Appendix 5 UH Bristol SAE processing flowchart within R&I

This flow chart is for use by R&I staff as a guidance document for handling SAEs reported to the UH Bristol R&I office for studies where UH Bristol or University of Bristol are acting as Sponsor. SAEs for studies sponsored by other organisations are not required to be sent to R&I. Please refer to the research safety reporting SOP for more information. A current version of the SOP can be found on the R&I website.

SAE report received into R&I department either via fax, email or post.

SAE report reviewed for completeness and entered onto SAE spreadsheet located: J:\Research and Innovation\Monitoring\Safety Reporting\SAE-SUSAR_Breaches_spreadsheet_v1.2_Aug 2015.xlsx *note PI signature must be recorded on SAE form or SAE form sent from PI email inbox (PI employer’s email account only – no personal accounts) to confirm PI review.

Where SAE form not complete Monitor/RMF chases research team (all within reporting timelines)

Monitor/RMF reviews expectedness, relatedness and seriousness and records this information on SAE spreadsheet identifying any requiring expedited reporting. Monitor/RMF also records whether SAE occurred in CTIMP or non CTIMP trial on spreadsheet.

IF SAE IS UNEXPECTED AND POSSIBLY, PROBABLY OR DEFINITELY RELATED (SUSAR) REQUIRES REPORTING TO REGULATORY AUTHORITIES- Refer to flowchart A

IF SAE is (a) expected or (b) unexpected and unlikely/not related to trial intervention, was it in a CTIMP?

YES

For all CTIMPs, provide SAE form and relevant SPC/IB to Head of Research & Innovation (or Research Operations manager in absence) for Sponsor review within 3 days of receipt of SAE. Attach queries form provided in Safety SOP appendix 5 for HoR&I to document any queries of SAE to be raised with PI or research team

Sponsor review disagrees or seeks further clarification from 3rd party on causality, relatedness and/or expectedness using Sponsor report form in Appendix 5 of Research Safety SOP. Head of R&I informs Monitor/RMF and contacts PI and CI to discuss.

If sponsor and CI continue to disagree and one review changes SAE to SUSAR- expedited process followed (refer to flowchart A) – Both reviews to be submitted to REC & MHRA

NO

For all non-CTIMPs RMF/Monitor to ensure completeness of report received and relevant information input into spreadsheet. No Head of R&I review required.

If SAE resolved SAE report to be filed in study folder (either hard copy if received via fax or electronic if received via email).

If SAE ongoing refer to flowchart B
Flowchart A  

IF SAE IS UNEXPECTED AND POSSIBLY, PROBABLY OR DEFINITELY RELATED (SUSAR) REQUIRES REPORTING TO REGULATORY AUTHORITIES

IF SUSAR is fatal or life threatening SUSAR to be reported to Ethics and MHRA within 7 days. Any other relevant information must be sent within 8 days of the report.

If SUSAR is non-fatal or non-life threatening, SUSAR to be reported to Ethics & MHRA within 15 days. The following processes described will occur within the appropriate timeframes depending on whether SUSAR is fatal or life threatening.

SUSAR OCCURRED IN CTIMP

For all CTIMPs, provide SAE form and relevant SPC/IB to Head of Research & Innovation (or Research Operations manager in absence) for Sponsor review within 3 days of receipt of SAE.

SUSAR OCCURRED IN NON-CTIMP

Monitor/RMF reviews SAE report – only provided to Head of R&I for review if issues identified.

Sponsor review disagrees or seeks further clarification from 3rd party on causality, relatedness and/or expectedness using Sponsor report form in Appendix 5 of Research Safety SOP – informs Monitor/RMF and Head of R&I contacts PI and CI to discuss.

Sponsor review in agreement with report

Sponsor and CI come to agreement.

Monitor/RMF liaison with research team and request they submit both CI SUSAR review and Sponsor SUSAR review to Ethics for information. RMF/Monitor complete e-SUSAR report with both assessments (CI and Sponsor) and notify research team when complete.

Monitor/RMF liaises with research team to ensure they submit to Ethics. Monitor/RMF completed e-SUSAR to MHRA and informs research team when complete.

If SUSAR is ongoing refer to flow chart B. If resolved, Monitor/RMF to file all paperwork in appropriate study location (electronic study file if appropriate). SAE spreadsheet information completed.
Flowchart B -

**SAE or SUSAR ongoing**

Monitor/RMF to note on SAE spreadsheet that SAE/SUSAR ongoing and requires follow up.

Monitor/RMF reminds teams who are unfamiliar of process that 1st follow up report required within 5 days. Monitor/RMF liaises with research team re additional information for SUSARs and requirements for those to be sent within 8 days of report to MHRA and REC.

Monitor/RMF reviews spreadsheet daily to identify SAEs/SUSARs with follow ups due and contacts team. SAEs/SUSARs kept within UH Bristol and UoB SAEs folder in RMF office until they are resolved (unless they are electronic where they will be stored in electronic study folder).

Monitor/RMF liaises with team until SAE resolved (referring to UH Bristol Research Safety Reporting SOP on process). A copy of the current SOP is stored within hard copy SAE and SOP folders in R&I office.

Once SAE resolved, Monitor/RMF updates spreadsheet and files correspondence and SAE in study folder if not already stored electronically.

Where SAE f-up forms not complete Monitor/RMF chases research team (all within reporting timelines)
### R&I Queries template about SAEs (UH Bristol/UoB sponsored CTIMPs)

<table>
<thead>
<tr>
<th>Study number</th>
<th>SAE number</th>
<th>Pt ID</th>
<th>Date of onset</th>
<th>Date study team aware of SAE</th>
<th>Date reported to R&amp;I</th>
<th>Date of review by R&amp;I</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### SAE/SUSAR SPONSOR REPORT FORM

**This page for Research and Innovation Use Only**

**UH Bristol sponsored Studies**

<table>
<thead>
<tr>
<th>Case reference number:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>UH Bristol Project Registration No:</td>
<td></td>
</tr>
<tr>
<td>EudraCT No (IMP trials only):</td>
<td></td>
</tr>
</tbody>
</table>

### 1. Independent 3rd party assessment of causality on behalf of Sponsor (if required)

**Is the SAE related to the drug/device/intervention?**

- [ ] Not related
- [ ] Unlikely to be related
- [ ] Possibly related*
- [ ] Probably related*
- [ ] Definitely related*

*If possibly, probably or definitely related, was the SAE unexpected?*

- [ ] Yes
- [ ] No

(Unexpected means not described in the protocol or other product information)

1 For unexpected SAEs, ensure all required sections of the follow up report form have been completed.

2 For expected SAEs, ensure sections 1, 2 and 3 of the follow up report form have been completed.

**Comments:**

Name of person performing sponsor assessment*

Contact Number:

Signature of person performing sponsor assessment:

Date:

### 2. Administrative and sponsor details

**Date report received from investigator:**

Name and Address of sponsor:

University Hospitals Bristol NHS Foundation Trust

Research and Development Department

Level 3

UH Bristol Education Centre

Upper Maudlin Street

Bristol BS2 8AE

Contact person at Sponsor

Name:

Address: Same as sponsor.

Telephone no: 0117 342 0233

Fax no: 0117 342 0239

* Where the assessment has been performed by the Data Safety Monitoring Board, give the name of the Chair and attach a list of names of the members of the Board who participated in the assessment.
**Appendix 7 – Corrective and Preventative Action Template**

<table>
<thead>
<tr>
<th>Title and Acronym (if available)</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Sponsor:</th>
<th>Funder:</th>
<th>R&amp;I ref number:</th>
<th>EudraCT number:</th>
<th>Principal Investigator:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Target recruitment:</th>
<th>Recruitment at time of breach:</th>
<th>Study start date:</th>
<th>Study end date:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Summary:**

How the issue/breach was identified and short summary (3-4 lines)

**Finding:**

<table>
<thead>
<tr>
<th>Corrective Actions:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Preventative Actions:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Acknowledged by:**

<table>
<thead>
<tr>
<th>Sponsor/ Host Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
</tr>
<tr>
<td>------</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name of Support Department (if relevant)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
</tr>
<tr>
<td>------</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
</tr>
<tr>
<td>------</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Please note that all incidents should be reported in line with relevant incident reporting policies at the NHS Trust involved. For further guidance on UH Bristol Incident Reporting processes, please follow the 'Incident Reporting' link on the connect homepage.
Appendix 8 - Guidance on content of Development Safety Update Reports

For Development Safety Update Report (DSUR) form go to Appendix 9.

A DSUR is IMP specific. If a Chief Investigator is carrying out more than one trial using the same IMP, one DSUR should be submitted for the IMP. This should occur on the first anniversary of the first regulatory approval in the world, and annually thereafter. For CTIMPS which have more than one IMP, the sponsor and the CI should agree the most appropriate approach to DSUR, and whether a single DSUR should be submitted for each IMP, or whether a combined DSUR should be submitted. Factors which will influence this decision are the dosing regime, form and the method(s) of administration.

The DSUR should have three parts:

**Part 1:** Analysis of the subjects’ safety in the concerned clinical trial(s) with an appraisal of its ongoing risk benefit.

**Part 2:** A line listing of all suspected SARs (including all SUSARs) occurred in the concerned trial, including all serious adverse reactions from third countries

**Part 3:** An aggregate summary tabulation of suspected SARs that occurred in the concerned trial

1. **Report on the subjects’ safety of a clinical trial** based on the information provided by investigators and the sponsor’s own assessments, the sponsor will report all new findings related to the safety of the IMP treatments in the concerned trial. Where UH Bristol is the sponsor, this will be delegated to the relevant research team to report. The concept of new findings refers to information not already present in the investigator’s brochure or, for licensed drugs, the summary of product characteristics. When relevant, the following points should be considered:
   a. relation with dose, duration, time course of the treatment
   b. reversibility
   c. evidence of previously unidentified toxicity in the trial subjects
   d. increased frequency of toxicity
   e. overdose and its treatment
   f. interactions or other associated risks factors
   g. any specific safety issues related to special populations, such as the elderly, the children or any other at risk groups.
   h. positive and negative experiences during pregnancy or lactation
   i. abuse
   j. risks which might be associated with the investigation or diagnostic procedures of the clinical trial

The report should also consider other experiences with the investigational medicinal product that are likely to affect the subjects’ safety. It should detail the measures previously or currently proposed to minimise the risks found where appropriate. Finally, a rationale must be given on whether or not it is necessary to amend the protocol, to change or update the consent form, patient information leaflet and the Investigator’s Brochure. This report will not replace the request for protocol amendments, which will follow its own specific procedure.

2. **Line-listings**

The annual report should contain a trial-specific line-listing of all reports of suspected SARs that were reported during this trial. The line listing provides key information but not necessarily all the details usually collected on individual cases. It should include each subject only once regardless of how many adverse reaction terms are reported for the case. If there is more than one reaction, they should all be mentioned but the case should be listed under the most serious adverse reaction.
reaction (sign, symptom or diagnosis) as judged by the sponsor. It is possible that the same subject may experience different adverse reactions on different occasions. Such experiences should be treated as separate reports. In such circumstances, the same subject might then be included in a line listing more than once and the line-listings should be cross-referenced when possible. Cases should be tabulated by body system (standard system organ classification scheme). The line listing identifiable by the sponsor listing reference number or date and time of printing should include the information per case as described in 2.1. Usually there should be one listing for each trial, but separate listings might be provided for active comparator or placebo or when appropriate and relevant for other reasons, e.g. in the case that in the same trial for different formulations, indications or routes of administration are studied.

2.1 Content of line listing
The line listing identifiable by the sponsor listing reference number or date and time of printing should include the following information per case:

a. clinical trial identification
b. Study subjects identification number in the trial
c. case reference number (Case-ID-Number) in the sponsor’s safety database for medicinal products
d. country in which case occurred
e. age and sex of trial subject
f. daily dose of investigational medicinal product, (and, when relevant, dosage form and route of administration)
g. date of onset of the adverse reaction. If not available, best estimate of time to onset from therapy initiation. For an ADR known to occur after cessation of therapy, estimate of time lag if possible.
h. dates of treatment (if not available, best estimate of treatment duration.)
i. adverse reaction: description of reaction as reported, and when necessary as interpreted by the sponsor, where medically appropriate, signs and symptoms can be grouped into diagnoses. MedDRA should be used.
j. patient’s outcome (e.g. resolved, fatal, improved, sequelae, unknown). This field should indicate the consequences of the reaction(s) for the patient, using the worst of the different outcomes for multiple reactions
k. comments, if relevant (e.g. causality assessment if the sponsor disagrees with the reporter; concomitant medications suspected to play a role in the reactions directly or by interaction; indication treated with suspect drug(s); dechallenge/rechallenge results if available)
l. unblinding results in the case of unblinded SUSARs expectedness at the time of the occurrence of the suspected SARs, assessed with the reference document (i.e. Investigator’s Brochure) in force at the beginning of the period covered by the report.

3. Aggregate summary tabulations
In addition to individual cases line listings, summary tabulations of SAR terms for signs, symptoms and/or diagnoses across all patients should usually be presented to provide an overview for each trial. These tabulations ordinarily contain more terms than subjects. When the number of cases is very small, a narrative description would be more suitable.

The aggregate summary tabulation should specify the number of reports:

a) for each body system
b) for each ADR term
c) for each treatment arm, if applicable (IMP, comparator or placebo, blinded treatment)

The unexpected ADR terms should be clearly identified in the tabulation. As an example, the table shown in section 3.1 can be used.
3.1 Example for an Aggregate Summary Tabulation

Number of reports by terms (signs, symptoms and diagnoses) for the trial number .......... 
(An * indicates an example of a SUSAR)

<table>
<thead>
<tr>
<th>Body system /ADR term</th>
<th>Verum</th>
<th>Placebo</th>
<th>Blinded</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CNS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hallucinations*</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Confusion*</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Sub-total</td>
<td>3</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td><strong>CV</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sub-total</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix 9 – Development Safety Update Report Form

DEVELOPMENT SAFETY UPDATE REPORT FOR IMP STUDIES – UH BRISTOL SPONSOR – UK STUDIES

For CTIMPs, on the first anniversary of (a) the date of the first Clinical Trials Authorisation (CTA) approval (trials starting after 1 May 2004) (b) the date of the original exemption (trials commenced under an exemption) or (c) the date of the first marketing authorisation granted in the EU (marketed products) and thereafter annually until the regulator has been informed of the closure of the trial a DSUR must be compiled and submitted. **Preparation and submission of the DSUR will be the responsibility of the Chief Investigator, supported and co-ordinated by the sponsor if required.** Submission should be made in accordance with the guidance on the MHRA website

And either submitted electronically via email or provided electronically on disk to:

- Research Ethics Committee that granted approval.

A copy should be placed within the Trial Master File and Investigator Site Files

**Instructions for completion:**

- Two months prior to the submission due date, **R&I will notify the Chief Investigator that a DSUR is due,** and advise the due date.
- **R&I will notify investigator of the location of the applicable template for completion**
- The **CI should complete the template and return the completed form** to the Research Management Office, Level 3, Education Centre, Upper Maudlin Street, Bristol BS2 8AE or to R&Dsponsrship@UHBristol.nhs.uk **within 21 days of notification.**
- **R&I will check the forms for completeness, complete section 11 if necessary and liaise with the CI over finalising the report, gain signatures and return to the CI.**
- The **CI should submit the completed forms to the MHRA following the submission guidance provided on the MHRA website.**
- A safety report form for the Research Ethics Committee should also be completed for CTIMPs. This form is available to download from the HRA website.

**NB unblinded information must not be revealed to the CI or research team if it would compromise the study.**
### DEVELOPMENT SAFETY UPDATE REPORT FORM - IMP STUDIES – UH Bristol SPONSOR - UK

#### 1. Details of Sponsor

<table>
<thead>
<tr>
<th>Organisation:</th>
<th>University Hospitals Bristol NHS Foundation Trust</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact person:</td>
<td>Head of Research &amp; Innovation/Research Operations Manager</td>
</tr>
<tr>
<td>Contact address:</td>
<td>Research and Innovation, Level 3, Education Centre, Upper Maudlin Street, Bristol BS2 8AE</td>
</tr>
<tr>
<td>Email address:</td>
<td><a href="mailto:research@uhbristol.nhs.uk">research@uhbristol.nhs.uk</a></td>
</tr>
<tr>
<td>Telephone No:</td>
<td>0117 342 0233</td>
</tr>
<tr>
<td>Fax number:</td>
<td>0117 342 0239</td>
</tr>
<tr>
<td>Signature:</td>
<td></td>
</tr>
</tbody>
</table>

| Name: | Date: |

#### 2. Details of person completing report

| Name: | |
| Job title/role in study: | |
| Contact address: | |
| Email address: | |
| Telephone No: | |
| Fax number: | |
| Signature: | |

| Name: | Date: |

#### 3. Details of DSUR

| Report number: | |
| Period Covered: | |
| Date of report: | |

#### 4. Details of IMP

| IMP(s): | |
| Dosage, form, route of administration: | |
| Supplier: | |
| Marketing status: | |

---

Page _____ of _____
### 5. Details of CTIMPs covered by report

<table>
<thead>
<tr>
<th>UH Bristol R&amp;D Project Registration No:</th>
<th>Ethics No:</th>
</tr>
</thead>
<tbody>
<tr>
<td>EudraCT No:</td>
<td>CTA No: (If CTA not yet issued, DDX no.)</td>
</tr>
</tbody>
</table>

**Full Title of Study:**

**Date of MHRA approval:**

---

<table>
<thead>
<tr>
<th>UH Bristol R&amp;D Project Registration No:</th>
<th>Ethics No:</th>
</tr>
</thead>
<tbody>
<tr>
<td>EudraCT No:</td>
<td>CTA No: (If CTA not yet issued, DDX no.)</td>
</tr>
</tbody>
</table>

**Full Title of Study:**

**Date of MHRA approval:**

---

<table>
<thead>
<tr>
<th>UH Bristol R&amp;D Project Registration No:</th>
<th>Ethics No:</th>
</tr>
</thead>
<tbody>
<tr>
<td>EudraCT No:</td>
<td>CTA No: (If CTA not yet issued, DDX no.)</td>
</tr>
</tbody>
</table>

**Full Title of Study:**

**Date of MHRA approval:**

---

### 6. Details of non-interventional studies using IMP (if applicable)

<table>
<thead>
<tr>
<th>UH Bristol R&amp;D Project Registration No:</th>
<th>Ethics No:</th>
</tr>
</thead>
</table>

**Full Title of Study:**

**Date of MHRA approval:**

---

### 7. Summary of Serious Adverse Events (SAEs)

<table>
<thead>
<tr>
<th>Number of SAEs</th>
<th>In reporting year:</th>
<th>In total:</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of SSARs</td>
<td>In reporting year:</td>
<td>In total:</td>
</tr>
<tr>
<td>No. of SUSARs</td>
<td>In reporting year:</td>
<td>In total:</td>
</tr>
</tbody>
</table>
8. Report on subjects’ safety in CTIMP(s), including urgent safety measures, serious breaches of GCP, temporary or early halt of trial due to safety concerns.

<table>
<thead>
<tr>
<th>EudraCT No:</th>
<th></th>
</tr>
</thead>
</table>

Are there any new findings\(^2\) related to the safety of the IMP treatments in this trial?  
Yes ☐  No ☐

If yes, provide details\(^3\):

Have there been any other experiences with this IMP that could affect the subjects’ safety?  
Yes ☐  No ☐

If yes, provide details:

Is/was it necessary to amend the protocol, patient information sheet, consent form or investigator brochure?  
Yes ☐  No ☐

If yes, give details (including amended version numbers and dates) and rationale:

Summary (including information gained from non-interventional studies and other sources, if applicable):

---

\(^2\) New findings refers to information not already present in the investigator’s brochure or for licensed drugs the summary of product characteristics.

\(^3\) When relevant, the following points should be considered: relation with dose, duration, time course of the treatment; reversibility; evidence of previously unidentified toxicity in the trial subjects; increased frequency of toxicity; overdose and its treatment; interactions or other associated risks factors; any specific safety issues related to special populations, such as the elderly, the children or any other at risk groups; positive and negative experiences during pregnancy or lactation; abuse; risks which might be associated with the investigation or diagnostic procedures of the clinical trial.
9. Overall safety assessment

Evaluation of risks:

Benefit-risk considerations:

Conclusions, including current management of risks and actions for future risk management if required:
10. Line listing of Suspected Serious Adverse Reactions (SSARs)

<table>
<thead>
<tr>
<th>Study Subject Id</th>
<th>AE No.</th>
<th>Age</th>
<th>Sex</th>
<th>Details of IMP(s) list all Name of IMP</th>
<th>Details of SSAR</th>
<th>Dates of IMP treatment</th>
<th>Description of adverse event</th>
<th>Outcome</th>
<th>Causality</th>
<th>Expected</th>
</tr>
</thead>
</table>

4 If not available, best estimate of time to onset and route of administration. For an ADR known to occur after cessation of therapy, estimate of time lag if possible.

5 If not available, best estimate of treatment duration

6 Possibly, probably or definitely related.

7 If causality/expectedness were uncertain and an unblinded assessment was carried out, team to liaise with R&I department who will assist with completing this section and ensuring appropriate team members remain blinded to allocation as required.
## 11. Aggregate Summary Table of SSARs

<table>
<thead>
<tr>
<th>Category</th>
<th>Adverse Event</th>
<th>Total No. of Reports</th>
</tr>
</thead>
<tbody>
<tr>
<td>e.g. Allergy/Immunology</td>
<td>e.g. Autoimmune reaction</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>